Ala20-Glu764, with C-terminal Human IgG1 Fc
ASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIEGRMDPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>95% by SDS-PAGE
Vascular endothelial cell growth factor (VEGF) and VEGF receptor 2 (VEGF-R2) are closely related to angiogenesis in glioma. A number of phosphorylated sites, such as Y801, Y951, Y1175, and Y1214 in the VEGF-R2 intracellular domains mediate critical signal transductions, including PI3K/AKT, MAPK, and PKC pathways. Main functions of VEGF-R2 include increasing the expression of VEGF and inducing tumor angiogenesis. In addition, VEGF plays a role in promoting vascular endothelial cell division and angiogenesis through VEGF-R2 and is also involved in promoting the aggressive growth of tumors. In the kidney, VEGF is almost exclusively expressed in glomerular and tubular epithelial cells, while the VEGF-R2 is mainly present in glomerular and tubular endothelial cells, as well as in interstitial cells. The present study shows that VEGF-R2 overexpression in advanced thyroid cancer maintains cancer malignancy and cell survival. Thus, selective targeting of VEGFR2/KDR signaling may be a potential strategy for advanced thyroid cancer treatment.
Immobilized VEGF165, Human (Cat. No. UA040019) at 0.5μg/mL (100μL/well) can bind VEGF-R2/KDR Fc Chimera, Human (Cat. No. UA010144) with EC50 of 0.020-0.038μg/ml.
Immobilized VEGF-121, Human (Cat. No. UA040082) at 2.0μg/mL (100μL/well) can bind VEGF-R2/KDR Fc Chimera, Human (Cat. No. UA010144) with EC50 of 8.25-11.55ng/mL.
VEGF-R2/KDR Fc Chimera, Human (Cat. No. UA010144) captured on Protein A Biosenor, can bind VEGF165, Human (Cat. No. UA040019) with an affinity constant of 1.35 μM as determined in SPR assay.
Protein A Chip captured VEGF-R2/KDR Fc Chimera, Human (Cat. No. UA010144), can bind VEGF-121, Human (Cat. No. UA040082) with an affinity constant of 75.40pM as determined in SPR assay.
您现在的位置：